No title
Adjuvant bacillus Calmette-Guérin (BCG) instillations represent a cornerstone in the treatment of non–muscle-invasive bladder cancer. Instillation schedule and dose modifications have been evaluated in efforts to reduce the incidence of adverse events (AEs), but none so far has the same treatment efficacy as the full-dose recommended schedule. It has been shown that prophylactic quinolone use in c
